Back to results
US 2026/0306592 A1Published application
Human factor vii deletion constructs for treating cancer
AssigneeThe Cleveland Clinic Foundation
InventorsJeongwu LEE, Hye-Min JEON
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, kits, and methods for treating a human subject with cancer (e.g., brain cancer) with a composition comprising: a human delta Factor VII construct, or nucleic acid sequence encoding said human delta Factor VII construct. In certain embodiments, the human delta Factor VII construct comprises a Propeptide domain and EGF-1 domain, or portions thereof, and lacks a functioning Peptidase S1 domain. In some embodiments, the human subject has glioblastoma and has been previously treated with radiation therapy.
Claims27
A composition comprising:
- a human delta Factor VII construct, or nucleic acid sequence encoding said human delta Factor VII construct,
- wherein said human delta Factor VII construct comprises:
- a) a human Factor VII Propeptide domain, or portion thereof with substantially the same activity,
- b) a human Factor VII EGF-1 domain, or portion thereof with substantially the same activity,
- and wherein said human delta Factor VII construct lacks a Peptidase S1 domain or lacks a functional Peptidase S1 domain, and
- wherein optionally said human delta Factor VII construct is less than 225 amino acids in length.
3 more elements
Dependencies are inferred from the claim text.